Reply to the comments by Anforth and Fernandez-Penas

dc.authorscopusid27867662800
dc.authorscopusid36870183300
dc.authorscopusid6701867255
dc.authorscopusid57213502354
dc.contributor.authorErfan, Gamze
dc.contributor.authorCarrera, Cristina
dc.contributor.authorMalvehy, J.
dc.contributor.authorPuig, S.
dc.date.accessioned2022-05-11T14:37:20Z
dc.date.available2022-05-11T14:37:20Z
dc.date.issued2017
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıkları Ana Bilim Dalı
dc.description.abstract[No abstract available]
dc.identifier.endpage1268
dc.identifier.issn0001-5555
dc.identifier.issue10en_US
dc.identifier.scopus2-s2.0-85032690166
dc.identifier.scopusqualityQ1
dc.identifier.startpage1267
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8660
dc.identifier.volume97
dc.indekslendigikaynakScopus
dc.institutionauthorErfan, Gamze
dc.language.isoen
dc.publisherMedical Journals/Acta D-V
dc.relation.ispartofActa Dermato-Venereologica
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectB Raf kinase inhibitor
dc.subjectdabrafenib
dc.subjectvemurafenib
dc.subjecterythema
dc.subjecthuman
dc.subjecthyperkeratosis
dc.subjectkeratoacanthoma
dc.subjectLetter
dc.subjectmetastatic melanoma
dc.subjectnon melanoma skin cancer
dc.subjectphotosensitivity
dc.subjectpriority journal
dc.subjectskin disease
dc.titleReply to the comments by Anforth and Fernandez-Penas
dc.typeLetter

Dosyalar